NLRP3 and metabolic dysfunction-associated steatotic liver disease: To further investigate the role of NLRP3 in the anti-NAFLD and anti-atherosclerosis effects of APN, NLRP3−/−Ldlr−/− mice were generated and fed with HFD with or without APN 50 for 8 weeks.